Magnesium oxide
Description
Type: small molecule
Groups: approved
Indication: Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.
Accession Number: DB01377 ( DB01377)
Description: Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. [PubChem]
Structure:
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
B6 Plus Tab | tablet | Array | oral | 31-12-1979 | 01-08-2002 | Canada |
Calcium Magnesium Tab | tablet | Array | oral | 31-12-1979 | 09-09-1996 | Canada |
Citracleen | powder for solution | Array | oral | 01-01-1970 | Canada | |
Cyclo/mag | kit | Array | Array | 09-03-2010 | US | |
Cyclo/mag 10mg/200mg | kit | Array | Array | 17-02-2010 | US | |
Kidmag Vitamins W Magnesium Tab | tablet | Array | oral | 31-12-1989 | 02-10-1996 | Canada |
Magnesium Cap | capsule | Array | oral | 31-12-1983 | 12-06-2002 | Canada |
Migralex Dr. Mauskop | tablet, coated | Array | oral | 15-11-2009 | US | |
One To One Cal-mag Tab 500mg | tablet | Array | oral | 31-12-1985 | 17-09-1997 | Canada |
Oral Purgative | powder for solution | Array | oral | 16-11-2011 | Canada | |
Pico-salax | powder for solution | Array | oral | 25-11-2004 | Canada | |
Picodan | powder for solution | Array | oral | 17-10-2007 | 31-12-2012 | Canada |
Picoflo | powder for solution | Array | oral | 25-03-2011 | Canada | |
Prenate Star | tablet, coated | Array | oral | 05-06-2014 | US | |
Purg-odan | powder for solution | Array | oral | 16-02-2009 | Canada | |
Strovite One Caplets | tablet | Array | oral | 04-05-2001 | US | |
Usana Active Calcium | tablet, chewable | Array | oral | 28-03-2012 | US | |
Virt-bal DHA Plus | kit | Array | Array | 12-07-2012 | US | |
Virt-PN | tablet, coated | Array | oral | 12-07-2012 | US | |
Virt-PN Plus | capsule, gelatin coated | Array | oral | 01-03-2013 | US |
Generic Prescription Products: Not Available
Over the Counter Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Magnesium Citrate Oral Solution | liquid | 1.75 g | oral | 31-12-1951 | 11-07-2003 | Canada |
Magnesium Oxide | tablet | 400 mg/1 | oral | 08-09-2015 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 15-07-2004 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 01-01-2013 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 09-04-2014 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 30-09-2014 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 03-12-2003 | US | |
Magnesium Oxide | tablet | 253 mg/1 | oral | 06-10-2003 | US | |
Magnesium Oxide 420 - Caplet | tablet | 250 mg | oral | 31-12-1995 | 18-07-2002 | Canada |
Magnesium Oxide Tab 420mg | tablet | 420 mg | oral | 31-12-1988 | 17-07-2008 | Canada |
Magnesium Tab 250mg | tablet | 410 mg | oral | 31-12-1987 | 05-07-2006 | Canada |
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
B6 Plus Tab | tablet | Array | oral | 31-12-1979 | 01-08-2002 | Canada |
Calcium Magnesium Tab | tablet | Array | oral | 31-12-1979 | 09-09-1996 | Canada |
Citracleen | powder for solution | Array | oral | 01-01-1970 | Canada | |
Cyclo/mag | kit | Array | Array | 09-03-2010 | US | |
Cyclo/mag 10mg/200mg | kit | Array | Array | 17-02-2010 | US | |
Kidmag Vitamins W Magnesium Tab | tablet | Array | oral | 31-12-1989 | 02-10-1996 | Canada |
Magnesium Cap | capsule | Array | oral | 31-12-1983 | 12-06-2002 | Canada |
Migralex Dr. Mauskop | tablet, coated | Array | oral | 15-11-2009 | US | |
One To One Cal-mag Tab 500mg | tablet | Array | oral | 31-12-1985 | 17-09-1997 | Canada |
Oral Purgative | powder for solution | Array | oral | 16-11-2011 | Canada | |
Pico-salax | powder for solution | Array | oral | 25-11-2004 | Canada | |
Picodan | powder for solution | Array | oral | 17-10-2007 | 31-12-2012 | Canada |
Picoflo | powder for solution | Array | oral | 25-03-2011 | Canada | |
Prenate Star | tablet, coated | Array | oral | 05-06-2014 | US | |
Purg-odan | powder for solution | Array | oral | 16-02-2009 | Canada | |
Strovite One Caplets | tablet | Array | oral | 04-05-2001 | US | |
Usana Active Calcium | tablet, chewable | Array | oral | 28-03-2012 | US | |
Virt-bal DHA Plus | kit | Array | Array | 12-07-2012 | US | |
Virt-PN | tablet, coated | Array | oral | 12-07-2012 | US | |
Virt-PN Plus | capsule, gelatin coated | Array | oral | 01-03-2013 | US |
Over the Counter Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Magnesium Citrate Oral Solution | liquid | 1.75 g | oral | 31-12-1951 | 11-07-2003 | Canada |
Magnesium Oxide | tablet | 400 mg/1 | oral | 08-09-2015 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 15-07-2004 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 01-01-2013 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 09-04-2014 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 30-09-2014 | US | |
Magnesium Oxide | tablet | 400 mg/1 | oral | 03-12-2003 | US | |
Magnesium Oxide | tablet | 253 mg/1 | oral | 06-10-2003 | US | |
Magnesium Oxide 420 - Caplet | tablet | 250 mg | oral | 31-12-1995 | 18-07-2002 | Canada |
Magnesium Oxide Tab 420mg | tablet | 420 mg | oral | 31-12-1988 | 17-07-2008 | Canada |
Magnesium Tab 250mg | tablet | 410 mg | oral | 31-12-1987 | 05-07-2006 | Canada |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
Brand Name | Ingredients |
---|---|
Magnesium Oxide | Magnesium oxide |
Magnesium Oxide | Magnesium oxide |
Strovite One Caplets | Vitamin A + Pantothenic acid + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Biotin + Cyanocobalamin + Selenium + Magnesium oxide + Zinc oxide + Cupric sulfate + Manganese + Chromium + Lipoic Acid + Lutein |
Magnesium Oxide | Magnesium oxide |
Migralex Dr. Mauskop | Acetylsalicylic acid + Magnesium oxide |
Usana Active Calcium | Calcium carbonate + Magnesium oxide + Cholecalciferol + Calcium citrate + Magnesium citrate |
Magnesium Oxide | Magnesium oxide |
Magnesium Oxide | Magnesium oxide |
Cyclo/mag | Cyclobenzaprine + Magnesium oxide |
Cyclo/mag 10mg/200mg | Cyclobenzaprine + Magnesium oxide |
Magnesium Oxide | Magnesium oxide |
Prenate Star | Beta carotene + Vitamin C + Cholecalciferol + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Cyanocobalamin + Biotin + Pantothenic acid + Formic Acid + Ferrous asparto glycinate + Potassium Iodide + Magnesium oxide + Zinc oxide + Cupric oxide |
Magnesium Oxide | Magnesium oxide |
Virt-bal DHA Plus | Folic Acid + Pyridoxine + Calcium carbonate + Sodium ascorbate + Cholecalciferol + Acetic acid + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Ferrous bisglycinate + Iodine + Zinc oxide + Cupric oxide + Beta carotene + Magnesium oxide + Doconexent + Icosapent |
Virt-PN | Levomefolic acid + Pyridoxine + Beta carotene + Calcium carbonate + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Iron + Potassium Iodide + Zinc oxide + Biotin + Pantothenic acid + Magnesium oxide + Cupric oxide |
Virt-PN Plus | Folic Acid + Vitamin C + Cholecalciferol + Vitamin E + Pyridoxine + Cyanocobalamin + Biotin + Calcium carbonate + Iron + Potassium Iodide + Magnesium oxide + Doconexent + Icosapent |
Pico-salax | Citric Acid + Sodium picosulfate + Magnesium oxide |
Purg-odan | Citric Acid + Sodium picosulfate + Magnesium oxide |
Picoflo | Citric Acid + Sodium picosulfate + Magnesium oxide |
Oral Purgative | Citric Acid + Sodium picosulfate + Magnesium oxide |
Magnesium Citrate Oral Solution | Magnesium oxide |
Magnesium Oxide 420 - Caplet | Magnesium oxide |
B6 Plus Tab | Thiamine + Riboflavin + Pyridoxine + Niacin + Potassium Citrate + Magnesium oxide |
Calcium Magnesium Tab | Calcium carbonate + Magnesium oxide |
Magnesium Cap | Magnesium oxide + Magnesium Sulfate |
One To One Cal-mag Tab 500mg | Calcium + Magnesium oxide |
Picodan | Citric Acid + Sodium picosulfate + Magnesium oxide |
Magnesium Tab 250mg | Magnesium oxide |
Magnesium Oxide Tab 420mg | Magnesium oxide |
Kidmag Vitamins W Magnesium Tab | Pyridoxine + Vitamin C + Vitamin A + Magnesium oxide |
Citracleen | Citric Acid + Sodium picosulfate + Magnesium oxide |
Brand Name | Ingredients |
---|---|
Magnesium Oxide | Magnesium oxide |
Magnesium Oxide | Magnesium oxide |
Strovite One Caplets | Vitamin A + Pantothenic acid + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Biotin + Cyanocobalamin + Selenium + Magnesium oxide + Zinc oxide + Cupric sulfate + Manganese + Chromium + Lipoic Acid + Lutein |
Magnesium Oxide | Magnesium oxide |
Migralex Dr. Mauskop | Acetylsalicylic acid + Magnesium oxide |
Usana Active Calcium | Calcium carbonate + Magnesium oxide + Cholecalciferol + Calcium citrate + Magnesium citrate |
Magnesium Oxide | Magnesium oxide |
Magnesium Oxide | Magnesium oxide |
Cyclo/mag | Cyclobenzaprine + Magnesium oxide |
Cyclo/mag 10mg/200mg | Cyclobenzaprine + Magnesium oxide |
Magnesium Oxide | Magnesium oxide |
Prenate Star | Beta carotene + Vitamin C + Cholecalciferol + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Cyanocobalamin + Biotin + Pantothenic acid + Formic Acid + Ferrous asparto glycinate + Potassium Iodide + Magnesium oxide + Zinc oxide + Cupric oxide |
Magnesium Oxide | Magnesium oxide |
Virt-bal DHA Plus | Folic Acid + Pyridoxine + Calcium carbonate + Sodium ascorbate + Cholecalciferol + Acetic acid + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Ferrous bisglycinate + Iodine + Zinc oxide + Cupric oxide + Beta carotene + Magnesium oxide + Doconexent + Icosapent |
Virt-PN | Levomefolic acid + Pyridoxine + Beta carotene + Calcium carbonate + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Iron + Potassium Iodide + Zinc oxide + Biotin + Pantothenic acid + Magnesium oxide + Cupric oxide |
Virt-PN Plus | Folic Acid + Vitamin C + Cholecalciferol + Vitamin E + Pyridoxine + Cyanocobalamin + Biotin + Calcium carbonate + Iron + Potassium Iodide + Magnesium oxide + Doconexent + Icosapent |
Pico-salax | Citric Acid + Sodium picosulfate + Magnesium oxide |
Purg-odan | Citric Acid + Sodium picosulfate + Magnesium oxide |
Picoflo | Citric Acid + Sodium picosulfate + Magnesium oxide |
Oral Purgative | Citric Acid + Sodium picosulfate + Magnesium oxide |
Magnesium Citrate Oral Solution | Magnesium oxide |
Magnesium Oxide 420 - Caplet | Magnesium oxide |
B6 Plus Tab | Thiamine + Riboflavin + Pyridoxine + Niacin + Potassium Citrate + Magnesium oxide |
Calcium Magnesium Tab | Calcium carbonate + Magnesium oxide |
Magnesium Cap | Magnesium oxide + Magnesium Sulfate |
One To One Cal-mag Tab 500mg | Calcium + Magnesium oxide |
Picodan | Citric Acid + Sodium picosulfate + Magnesium oxide |
Magnesium Tab 250mg | Magnesium oxide |
Magnesium Oxide Tab 420mg | Magnesium oxide |
Kidmag Vitamins W Magnesium Tab | Pyridoxine + Vitamin C + Vitamin A + Magnesium oxide |
Citracleen | Citric Acid + Sodium picosulfate + Magnesium oxide |
Categories
- Antacids
Pharmacology
Pharmacodynamics: Not Available
Mechanism of action: The term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
- Not Available
Packagers:
- Bayer Healthcare
- Blaine Pharmaceuticals
- Gallipot
- Major Pharmaceuticals
- Manne Co.
- Mckesson Corp.
- Particle Dynamics Co.
- Qualitest
- Rising Pharmaceuticals
- Rugby Laboratories
- Walgreen Co.
Dosage forms
Form | Route | Strength |
---|---|---|
Kit | ||
Capsule | oral | |
Liquid | oral | 1.75 g |
Tablet | oral | 253 mg/1 |
Tablet | oral | 400 mg/1 |
Tablet | oral | 250 mg |
Tablet | oral | 420 mg |
Tablet | oral | 410 mg |
Tablet, coated | oral | |
Powder for solution | oral | |
Tablet | oral | |
Tablet, chewable | oral | |
Capsule, gelatin coated | oral |
Form | Route | Strength |
---|---|---|
Kit | ||
Capsule | oral | |
Liquid | oral | 1.75 g |
Tablet | oral | 253 mg/1 |
Tablet | oral | 400 mg/1 |
Tablet | oral | 250 mg |
Tablet | oral | 420 mg |
Tablet | oral | 410 mg |
Tablet, coated | oral | |
Powder for solution | oral | |
Tablet | oral | |
Tablet, chewable | oral | |
Capsule, gelatin coated | oral |
Prices
Unit description | Cost | Unit |
---|---|---|
Magnesium oxide 250 mg tablet | $0.03 | tablet |
Magnesium oxide 500 mg tablet | $0.04 | tablet |
Maox 420 mg tablet | $0.04 | tablet |
Magnesium oxide powder heavy | $0.05 | g |
Mag-oxide 400 mg tablet | $0.09 | tablet |
Magnesium oxide 420 mg tablet | $0.11 | tablet |
Magox 400 tablet | $0.11 | tablet |
Magnesium oxide 400 mg tablet | $0.13 | tablet |
Phillips 500 mg caplet | $0.18 | caplet |
Unit description | Cost | Unit |
---|---|---|
Magnesium oxide 250 mg tablet | $0.03 | tablet |
Magnesium oxide 500 mg tablet | $0.04 | tablet |
Maox 420 mg tablet | $0.04 | tablet |
Magnesium oxide powder heavy | $0.05 | g |
Mag-oxide 400 mg tablet | $0.09 | tablet |
Magnesium oxide 420 mg tablet | $0.11 | tablet |
Magox 400 tablet | $0.11 | tablet |
Magnesium oxide 400 mg tablet | $0.13 | tablet |
Phillips 500 mg caplet | $0.18 | caplet |
Patents
Country | Patent Number | Approved | Expires (estimated) |
---|
Interactions
Drug | Interaction |
---|---|
Alendronate | The serum concentration of Alendronate can be decreased when it is combined with Magnesium oxide. |
Alfacalcidol | The serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol. |
Allopurinol | Magnesium oxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide. |
Amphetamine | Magnesium oxide may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Amrinone | The risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium oxide. |
Atazanavir | Magnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Atorvastatin | The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide. |
Benzphetamine | Magnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Bepridil | The risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide. |
Biotin | Magnesium oxide can cause a decrease in the absorption of Biotin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide. |
Bosutinib | The serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide. |
Budesonide | The bioavailability of Budesonide can be decreased when combined with Magnesium oxide. |
Calcitriol | The serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol. |
Captopril | The serum concentration of Captopril can be decreased when it is combined with Magnesium oxide. |
Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide. |
Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide. |
Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide. |
Chloroquine | The serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide. |
Chlorpromazine | Magnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Ciprofloxacin | Magnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Clodronate | The serum concentration of Clodronate can be decreased when it is combined with Magnesium oxide. |
Cortisone acetate | The bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide. |
Cysteamine | The therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium oxide. |
Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide. |
Dabrafenib | The serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide. |
Dasatinib | Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Deferiprone | The serum concentration of Deferiprone can be decreased when it is combined with Magnesium oxide. |
Delavirdine | The serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide. |
Demeclocycline | Magnesium oxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Dexamethasone | The bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide. |
Dexmethylphenidate | Magnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
Dextroamphetamine | Magnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Dolutegravir | The serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide. |
Doxycycline | Magnesium oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Eltrombopag | The serum concentration of Eltrombopag can be decreased when it is combined with Magnesium oxide. |
Elvitegravir | The serum concentration of Elvitegravir can be decreased when it is combined with Magnesium oxide. |
Erlotinib | The serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide. |
Felodipine | The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide. |
Fexofenadine | The serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide. |
Fludrocortisone | The bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide. |
Flunarizine | The risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide. |
Fluphenazine | Magnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Fluvastatin | The serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide. |
Fosinopril | The serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide. |
Gabapentin | Magnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin. |
Gefitinib | The serum concentration of Gefitinib can be decreased when it is combined with Magnesium oxide. |
Gemifloxacin | Magnesium oxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Hexamethylenetetramine | The therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium oxide. |
Hydrocortisone | The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide. |
Hyoscyamine | The serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide. |
Ibandronate | The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide. |
Isoniazid | Magnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Isradipine | The risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide. |
Itraconazole | The serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide. |
Ketoconazole | The serum concentration of Ketoconazole can be decreased when it is combined with Magnesium oxide. |
Lamotrigine | The risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide. |
Ledipasvir | The serum concentration of Ledipasvir can be decreased when it is combined with Magnesium oxide. |
Lercanidipine | The risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide. |
Levofloxacin | Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Levothyroxine | The serum concentration of Levothyroxine can be decreased when it is combined with Magnesium oxide. |
Lipoic Acid | Magnesium oxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Lisdexamfetamine | Magnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Lovastatin | The serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide. |
Magnesium Sulfate | The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide. |
Mesalazine | The therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide. |
Methamphetamine | Magnesium oxide may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Methotrimeprazine | Magnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Methylphenidate | Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
Methylprednisolone | The bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide. |
Minocycline | Magnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Misoprostol | The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol. |
Moxifloxacin | Magnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Mycophenolate mofetil | Magnesium oxide can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide. |
Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide. |
Nilotinib | The serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide. |
Nimodipine | The risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide. |
Nisoldipine | The risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide. |
Nitrendipine | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide. |
Norfloxacin | Magnesium oxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Ofloxacin | Magnesium oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Oxytetracycline | Magnesium oxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Pazopanib | The serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide. |
Penicillamine | The serum concentration of Penicillamine can be decreased when it is combined with Magnesium oxide. |
Perhexiline | The risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium oxide. |
Perphenazine | Magnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Phendimetrazine | Magnesium oxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy. |
Phentermine | Magnesium oxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy. |
Pipotiazine | Magnesium oxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Pitavastatin | The serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide. |
Polystyrene sulfonate | The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Polystyrene sulfonate. |
Pravastatin | The serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide. |
Prednisolone | The bioavailability of Prednisolone can be decreased when combined with Magnesium oxide. |
Prednisone | The bioavailability of Prednisone can be decreased when combined with Magnesium oxide. |
Prenylamine | The risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide. |
Prochlorperazine | Magnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Promazine | Magnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Quinidine | Magnesium oxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy. |
Quinine | The serum concentration of Quinine can be decreased when it is combined with Magnesium oxide. |
Raltegravir | The serum concentration of Raltegravir can be decreased when it is combined with Magnesium oxide. |
Rilpivirine | The serum concentration of Rilpivirine can be decreased when it is combined with Magnesium oxide. |
Riociguat | The serum concentration of Riociguat can be decreased when it is combined with Magnesium oxide. |
Risedronate | The serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide. |
Rosuvastatin | The serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide. |
Simvastatin | The serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide. |
Sofosbuvir | The serum concentration of Sofosbuvir can be decreased when it is combined with Magnesium oxide. |
Sotalol | The serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide. |
Sparfloxacin | The serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium oxide. |
Tetracycline | Magnesium oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Thioridazine | Magnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Tiludronate | The serum concentration of Tiludronate can be decreased when it is combined with Magnesium oxide. |
Triethylenetetramine | The serum concentration of Magnesium oxide can be decreased when it is combined with Triethylenetetramine. |
Trifluoperazine | Magnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Verapamil | The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide. |
Drug | Interaction |
---|---|
Alendronate | The serum concentration of Alendronate can be decreased when it is combined with Magnesium oxide. |
Alfacalcidol | The serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol. |
Allopurinol | Magnesium oxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Amlodipine | The risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide. |
Amphetamine | Magnesium oxide may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Amrinone | The risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium oxide. |
Atazanavir | Magnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Atorvastatin | The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide. |
Benzphetamine | Magnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Bepridil | The risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide. |
Biotin | Magnesium oxide can cause a decrease in the absorption of Biotin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide. |
Bosutinib | The serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide. |
Budesonide | The bioavailability of Budesonide can be decreased when combined with Magnesium oxide. |
Calcitriol | The serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol. |
Captopril | The serum concentration of Captopril can be decreased when it is combined with Magnesium oxide. |
Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide. |
Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide. |
Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide. |
Chloroquine | The serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide. |
Chlorpromazine | Magnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Ciprofloxacin | Magnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Clodronate | The serum concentration of Clodronate can be decreased when it is combined with Magnesium oxide. |
Cortisone acetate | The bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide. |
Cysteamine | The therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium oxide. |
Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide. |
Dabrafenib | The serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide. |
Dasatinib | Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Deferiprone | The serum concentration of Deferiprone can be decreased when it is combined with Magnesium oxide. |
Delavirdine | The serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide. |
Demeclocycline | Magnesium oxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Dexamethasone | The bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide. |
Dexmethylphenidate | Magnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
Dextroamphetamine | Magnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Dolutegravir | The serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide. |
Doxycycline | Magnesium oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Eltrombopag | The serum concentration of Eltrombopag can be decreased when it is combined with Magnesium oxide. |
Elvitegravir | The serum concentration of Elvitegravir can be decreased when it is combined with Magnesium oxide. |
Erlotinib | The serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide. |
Felodipine | The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide. |
Fexofenadine | The serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide. |
Fludrocortisone | The bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide. |
Flunarizine | The risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide. |
Fluphenazine | Magnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Fluvastatin | The serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide. |
Fosinopril | The serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide. |
Gabapentin | Magnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin. |
Gefitinib | The serum concentration of Gefitinib can be decreased when it is combined with Magnesium oxide. |
Gemifloxacin | Magnesium oxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Hexamethylenetetramine | The therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium oxide. |
Hydrocortisone | The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide. |
Hyoscyamine | The serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide. |
Ibandronate | The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide. |
Isoniazid | Magnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Isradipine | The risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide. |
Itraconazole | The serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide. |
Ketoconazole | The serum concentration of Ketoconazole can be decreased when it is combined with Magnesium oxide. |
Lamotrigine | The risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide. |
Ledipasvir | The serum concentration of Ledipasvir can be decreased when it is combined with Magnesium oxide. |
Lercanidipine | The risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide. |
Levofloxacin | Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Levothyroxine | The serum concentration of Levothyroxine can be decreased when it is combined with Magnesium oxide. |
Lipoic Acid | Magnesium oxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Lisdexamfetamine | Magnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Lovastatin | The serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide. |
Magnesium Sulfate | The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide. |
Mesalazine | The therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide. |
Methamphetamine | Magnesium oxide may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy. |
Methotrimeprazine | Magnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Methylphenidate | Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
Methylprednisolone | The bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide. |
Minocycline | Magnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Misoprostol | The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol. |
Moxifloxacin | Magnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Mycophenolate mofetil | Magnesium oxide can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide. |
Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide. |
Nilotinib | The serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide. |
Nimodipine | The risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide. |
Nisoldipine | The risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide. |
Nitrendipine | The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide. |
Norfloxacin | Magnesium oxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Ofloxacin | Magnesium oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Oxytetracycline | Magnesium oxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Pazopanib | The serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide. |
Penicillamine | The serum concentration of Penicillamine can be decreased when it is combined with Magnesium oxide. |
Perhexiline | The risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium oxide. |
Perphenazine | Magnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Phendimetrazine | Magnesium oxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy. |
Phentermine | Magnesium oxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy. |
Pipotiazine | Magnesium oxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Pitavastatin | The serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide. |
Polystyrene sulfonate | The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Polystyrene sulfonate. |
Pravastatin | The serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide. |
Prednisolone | The bioavailability of Prednisolone can be decreased when combined with Magnesium oxide. |
Prednisone | The bioavailability of Prednisone can be decreased when combined with Magnesium oxide. |
Prenylamine | The risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide. |
Prochlorperazine | Magnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Promazine | Magnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Quinidine | Magnesium oxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy. |
Quinine | The serum concentration of Quinine can be decreased when it is combined with Magnesium oxide. |
Raltegravir | The serum concentration of Raltegravir can be decreased when it is combined with Magnesium oxide. |
Rilpivirine | The serum concentration of Rilpivirine can be decreased when it is combined with Magnesium oxide. |
Riociguat | The serum concentration of Riociguat can be decreased when it is combined with Magnesium oxide. |
Risedronate | The serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide. |
Rosuvastatin | The serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide. |
Simvastatin | The serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide. |
Sofosbuvir | The serum concentration of Sofosbuvir can be decreased when it is combined with Magnesium oxide. |
Sotalol | The serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide. |
Sparfloxacin | The serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium oxide. |
Tetracycline | Magnesium oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Thioridazine | Magnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Tiludronate | The serum concentration of Tiludronate can be decreased when it is combined with Magnesium oxide. |
Triethylenetetramine | The serum concentration of Magnesium oxide can be decreased when it is combined with Triethylenetetramine. |
Trifluoperazine | Magnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
Verapamil | The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide. |
Food Interactions:
- Not Available
Taxonomy
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
- Acyclic compound
- Inorganic oxide
- Miscellaneous mixed metal/non-metal
References
General Reference: # Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R: Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens. 2000 Jul;18(7):919-26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10930190 # Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S: Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999 Jul 15;84(2):152-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10426331
External Links:
Resource | Link |
---|---|
Drugs.com | http://www.drugs.com/cdi/magnesium-oxide.html |
Resource | Link |
---|---|
Drugs.com | http://www.drugs.com/cdi/magnesium-oxide.html |
ATC Codes:
- Array
- Array
- Array
AHFS Codes:
- 88:29.00*
- 92:02.00*
MSDS: Download